161115-59-9

Basic information

• Product Name: Desisobutyryl Ciclesonide
• Synonyms: 21-Desisobutyryl Ciclesonide;(2′R)-2′-Cyclohexyl-11b,21-dihydroxy-16bH-[1,3]dioxolo[4′,5′:16,17]pregna-1,4-diene-3,20-dione;Ciclesonide impurity B;Desisobutyryl Ciclesonide;(11β,16α)-16,17-[[(R)-CyclohexylMethylene]bis(oxy)]-11,21-dihydroxypregna-1,4-diene-3,20-dione;CIC-AP;Ciclesonide active principle
• CAS NO: 161115-59-9
• Molecular Formula: C₂₈H₃₈O₆
• Molecular Weight: 470.59772
• Product Categories: Intermediates & Fine Chemicals;Pharmaceuticals;Steroids
• Mol File: 161115-59-9.mol

Chemical Properties

• Melting Point: 129-132?C
• Boiling Point: 640.778 °C at 760 mmHg
• Flash Point: 211.522 °C
• Appearance: /
• Density: 1.284g/cm³
• Storage Temp.: -20°C Freezer
• Solubility: Chloroform (Slightly), Methanol (Slightly)
• PKA: 12.87±0.10(Predicted)
• CAS DataBase Reference: Desisobutyryl Ciclesonide(CAS DataBase Reference)
• NIST Chemistry Reference: Desisobutyryl Ciclesonide(161115-59-9)
• EPA Substance Registry System: Desisobutyryl Ciclesonide(161115-59-9)

Safety Data

• Hazardous Substances Data: 161115-59-9(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Desisobutyryl Ciclesonide is used as an anti-inflammatory agent for the treatment of asthma. It exhibits potent anti-inflammatory properties, making it a promising candidate for managing asthma symptoms and improving the quality of life for patients suffering from this respiratory condition.
Additionally, due to its corticosteroid nature, Desisobutyryl Ciclesonide may also be utilized in other medical applications where anti-inflammatory and immunosuppressive effects are required, such as in the treatment of chronic obstructive pulmonary disease (COPD), allergic rhinitis, and various skin conditions like eczema and dermatitis. However, further research and clinical trials are necessary to establish its efficacy and safety in these additional applications.

Upstream product

• 91160-89-3 9α-bromo-11β,16α,17α,21-tetrahydroxypregnane-1,4-diene-3,20-dione-21-acetate 
• 77017-20-0 16α,17α,21-trihydroxypregna-1,4,9(11)-triene-3,20-dione-21-acetate 
• 37413-91-5 2-((10S,13S,14S)-10,13-dimethyl-3-oxo-6,7,8,10,12,13,14,15-octahydro-3H-cyclopenta[a]phenanthren-17-yl)-2-oxoethyl acetate 
• 13951-70-7 desonide 
• 2043-61-0 cyclohexanecarbaldehyde 
• 638-94-8 desonide 
• 86401-80-1 11β,16α,17α,21-tetrahydroxypregnane-1,4-diene-3,20-dione-21-acetate 
• 126544-47-6 ciclesonide 

Downstream Products

• 126544-47-6 ciclesonide 
• 917480-23-0 16,17-[(cyclohexylmethylene)bis(oxy)]-11-hydroxy-21-(N,N-dimethylamino)-pregna-1,4-diene-3,20-dione[11β,16α(R)] 
• 1451396-66-9 21-bromo-16α,17-[(R)-cyclohexylmethylenedioxy]-11β-hydroxypregna-1,4-dien-3,20-dione 
• 1243575-79-2 C₄₂H₅₇NO₁₄ 
• 1243575-80-5 C₄₂H₅₇NO₁₄ 
• 1243575-77-0 C₄₀H₅₄O₁₃ 
• 1243575-78-1 C₄₀H₅₄O₁₃ 
• 1243575-85-0 C₃₄H₄₈O₁₀ 
• 1243575-76-9 C₅₄H₅₆O₁₉ 
• 1243575-75-8 C₃₈H₄₈O₁₅ 
• 1243575-74-7 C₅₀H₇₂O₁₅ 
• 1243575-72-5 C₅₀H₇₂O₁₅ 
• 1243575-71-4 C₄₆H₆₄O₁₅ 
• 1243575-70-3 C₄₂H₅₆O₁₅ 

Relevant articles and documents

Preparation method of ciclesonide

The invention discloses a preparation method of ciclesonide. The preparation method comprises the following steps: aldolization reaction, primary purification, hydrolysis reaction, esterification reaction and secondary purification. Aldolization reaction:

Ciclesonide preparation method

The invention discloses a ciclesonide preparation method, and belongs to the technical field of pharmacy, wherein 16[alpha]-hydroxyprednisolone-21-acetate (the previous-step intermediate of 16[alpha]-hydroxyprednisolone) is used as a starting raw material

Pregnane derivatives 16, 17 - acetal (ketone) preparation method

Disclosed is a method for preparing a pregnane derivative 16,17-acetal (ketal) compound shown in the general formula I, the method comprising the step of reacting a compound of a general formula II with a compound of a general formula III or a general formula IV in the presence of boron trifluoride, wherein the dotted line between site 1 and site 2 denotes a saturated or unsaturated bond; R is hydroxyl, halogen or -OCOR7, wherein R7 is a C1-C12 linear chain or branched alkyl, a C3-C10 cycloalkyl, a C2-C8 alkenyl or a C2-C8 alkynyl; R1 and R2 are each hydrogen, a C1-C12 linear chain or branched alkyl, a C3-C10 cycloalkyl, a C2-C8 alkenyl or a C2-C8 alkynyl, or R1, R2 and the carbon to which they are connected form a C3-C10 cycloalkyl together, with the provision that R1 and R2 are not hydrogen simultaneously; R3 is hydrogen or -OCOR8, wherein R8 is a C1-C12 linear chain or branched alkyl, or a C3-C10 cycloalkyl; R4 is hydrogen, fluorine or chlorine; R5 is hydrogen, fluorine, chlorine or methyl; and R6 is a C1-C12 linear chain or branched alkyl. Compared with current processes, the method causes little pollution to the environment, has relatively mild reaction conditions, ease of control, reduced energy consumption and low production costs.

NOVEL PROCESS FOR PREPARATION OF GLUCOCORTICOID STEROIDS

The present invention discloses a process for the preparation of 16, 17-acetals of pregnane derivatives having formula (I) wherein each substituent is independently selected from; R1 is H or CH3; R2 is C1-C6 linear or branched alkyl, alkynyl group or cycloalkyl group; aryl or heteroaryl group; or R1 and R2 combine to form saturated, unsaturated C3-C6 cyclic or heterocyclic ring; R3 and R4 are same or different and each independently represents H or halogen; R5 is -OH or –OCOR wherein R represents H or C1-C6 linear, branched or cyclic alkyl group that may be substituted.

STEROID COMPOUND

A steroid compound of the Formula (1): [wherein R1 represents a group selected from the group consisting of H, CH3, C2H5, C3H7 and CH (CH3)2, R2 represents a group selected from NH2, NHAc and OCOR1, R3 represents a group selected from the group consisting of CH3, COOCH3 and CH2OCOR1.]

STEROID COMPOUND

A steroid compound of the Formula (1): [wherein R1 represents a group selected from the group consisting of H, CH3, C2H5, C3H7 and CH (CH3)2, R2 represents a group selected from NH2, NHAc and OCOR1, R3 represents a group selected from the group consisting of CH3, COOCH3 and CH2OCOR1.]

Crystalline Ciclesonide Methanol Solvate Form C

The present invention relates to crystalline ciclesonide methanol solvate Form C, processes for its preparation, its use in the synthesis of crystalline ciclesonide Form A and its use in medicine.

PROCESSES FOR THE PREPARATION OF CICLESONIDE AND ITS CRYSTAL MODIFICATION

Improved processes for the synthesis of ciclesonide, chemically termed as [11β,16α(R)]-16,17-[(cyclohexylmethylene)bis(oxy)]-11-hydroxy-21-(2-methyl-1-oxopropoxy)pregna-1,4-diene-3,20-dione and its crystal modification.

PROCESS FOR THE PREPARATION OF PREGNANE DERIVATIVES

A stereoselective and enrichment process for the preparation of ciclesonide is described.

Process for the preparation of ciclesonide

Provided is a process for increasing the 22R/22S epidemic ratio of ciclesonide.